Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, UK.
Department of Vascular Surgery, Royal Victoria Hospital, Belfast, UK.
Clin Endocrinol (Oxf). 2024 Sep;101(3):243-248. doi: 10.1111/cen.15070. Epub 2024 May 2.
Head and neck paragangliomas (HNPGLs) are rare, usually benign, slow-growing tumours arising from neural crest-derived tissue. Definitive management pathways for HNPGLs have yet to be clearly defined.
To review our experience of the clinical features and management of these tumours and to analyse outcomes of different treatment modalities.
Demographic and clinical data were obtained from The Northern Ireland Electronic Care Record (NIECR) as well from a prospectively maintained HNPGL database between January 2011 through December 2023.
There were 87 patients; 50 females: 37 males with a mean age of 52.3 ± 14.2 years old (range 17-91 years old). 58.6% (n = 51) of patients had carotid body tumours, 25.2% (n = 22) glomus vagal tumours, 6.8% (n = 6) tumours in the middle ear, 2.2% (n = 2) in the parapharyngeal space and 1.1% (n = 1) in the sphenoid sinus. 5.7% (n = 5) of patients had multifocal disease. The mean tumour size at presentation was 3.2 ± 1.4 cm (range 0.5-6.9 cm). Pathogenic SDHD mutations were identified in 41.3% (n = 36), SDHB in 12.6% (n = 11), SDHC in 2.2% (n = 2) and SDHA in 1.1% (n = 1) of the patients. Overall treatment modalities included surgery alone in 51.7% (n = 45) of patients, radiotherapy in 14.9% (n = 13), observation in 28.7% (n = 25), and somatostatin analogue therapy with octreotide in 4.5% (n = 4) of patients. Factors associated with a significantly higher risk of recurrence included age over 60 years (p = .04), tumour size exceeding 2 cm (p = .03), positive SDHx variants (p = .01), and vagal and jugular tumours (p = .04).
The majority of our patients underwent initial surgical intervention and achieved disease stability. Our results suggest that carefully selected asymptomatic or medically unfit patients can be safely observed provided lifelong surveillance is maintained. We advocate for the establishment of a UK and Ireland national HNPGL registry, to delineate optimal management strategies for these rare tumours and improve long term outcomes.
头颈部副神经节瘤(HNPGL)是一种罕见的、通常为良性的、生长缓慢的肿瘤,起源于神经嵴衍生组织。HNPGL 的明确治疗途径尚未明确界定。
回顾我们对这些肿瘤的临床特征和管理的经验,并分析不同治疗方式的结果。
从北爱尔兰电子病历(NIECR)以及 2011 年 1 月至 2023 年 12 月期间前瞻性维护的 HNPGL 数据库中获取人口统计学和临床数据。
共纳入 87 例患者;女性 50 例,男性 37 例,平均年龄为 52.3±14.2 岁(17-91 岁)。58.6%(n=51)的患者为颈动脉体瘤,25.2%(n=22)为迷走神经节瘤,6.8%(n=6)为中耳肿瘤,2.2%(n=2)为咽旁间隙肿瘤,1.1%(n=1)为蝶窦肿瘤。5.7%(n=5)的患者有多发性疾病。发病时肿瘤平均大小为 3.2±1.4cm(0.5-6.9cm)。41.3%(n=36)患者存在致病性 SDHD 突变,12.6%(n=11)存在 SDHB 突变,2.2%(n=2)存在 SDHC 突变,1.1%(n=1)存在 SDHA 突变。总体治疗方式包括手术单独治疗 51.7%(n=45)、放疗 14.9%(n=13)、观察 28.7%(n=25)、生长抑素类似物奥曲肽治疗 4.5%(n=4)。与复发风险显著增加相关的因素包括年龄大于 60 岁(p=0.04)、肿瘤直径大于 2cm(p=0.03)、SDHx 变异阳性(p=0.01)以及迷走神经和颈静脉肿瘤(p=0.04)。
我们的大多数患者最初接受了手术干预,并实现了疾病稳定。我们的结果表明,对于无症状或不适合接受治疗的精心选择的患者,可以在终身监测的情况下安全观察。我们主张建立一个英国和爱尔兰的 HNPGL 登记处,以确定这些罕见肿瘤的最佳治疗策略,并改善长期结果。